https://www.selleckchem.com/pr....oducts/proteinase-k.
BACKGROUND Pulmonary sarcomatoid carcinoma (PSC) or pleomorphic carcinoma is a rare subtype of non-small cell lung cancer. Some reports have suggested the efficacy of checkpoint inhibitor immunotherapy for PSC. However, owing to the small number of patients in each report, it remains unclear whether programmed death receptor-ligand 1 (PD-L1) expression is predictive of tumor response or survival. PATIENTS AND METHODS The English literature was systematically searched for articles published from 2015 to 2019 and reported on tumor re
Like
Comment
Share
